Leadership Overview
Revance Therapeutics has 6 executives leading key functions including strategy, financial oversight, operational scaling, human capital, revenue generation, and legal compliance.
Focused on advancing biotechnology innovation, Revance Therapeutics delivers novel botulinum toxin products to transform aesthetic and therapeutic patient care through rigorous clinical development and commercial excellence.
Focused on advancing biotechnology innovation, Revance Therapeutics delivers novel botulinum toxin products to transform aesthetic and therapeutic patient care through rigorous clinical development and commercial excellence.
Leadership Roles at Revance Therapeutics
Nadeem Moiz - Chief Executive Officer
Nadeem Moiz, the Chief Executive Officer at Revance Therapeutics, directs the overarching corporate strategy and long-term vision for the biotechnology firm. Overseeing the development and commercialization of DaxibotulinumtoxinA, the Chief Executive Officer ensures alignment between clinical trial milestones and market entry requirements. This leadership role involves constant engagement with the Board to secure capital and maintain investor confidence during critical Phase III trials. By prioritizing innovation in botulinum toxin products, Nadeem Moiz drives the company toward sustainable growth within the competitive aesthetic and therapeutic landscape. The Chief Executive Officer manages high-level partnerships and regulatory interactions to solidify the market position of the organization. Ultimately, Moiz secures the future of the enterprise by fostering a culture of scientific excellence and operational discipline across all departments.
Scott Leffler - Chief Financial Officer
Scott Leffler, the Chief Financial Officer at Revance Therapeutics, manages the fiscal health and capital allocation strategies necessary for advanced pharmaceutical research. Overseeing financial planning, reporting, and treasury functions, the Chief Financial Officer ensures the company maintains sufficient liquidity to fund ongoing clinical trials for RT002 and RT001. This leadership role involves rigorous analysis of market trends and cost structures to optimize resource distribution across North American operations. By implementing robust financial controls, Scott Leffler supports the long-term viability of the biotechnology pipeline. The Chief Financial Officer coordinates with external auditors and investors to provide transparency regarding the financial trajectory of the firm. Ultimately, Leffler strengthens the balance sheet, enabling the organization to pursue aggressive development goals while maintaining fiscal responsibility in a volatile industry.
Nicholas Crowe - Chief Operating Officer
Nicholas Crowe, the Chief Operating Officer at Revance Therapeutics, architects the internal infrastructure and manufacturing processes required to scale production of novel botulinum toxin products. Overseeing supply chain logistics and quality assurance, the Chief Operating Officer ensures that clinical-grade materials meet stringent regulatory standards for both aesthetic and therapeutic applications. This leadership role involves streamlining cross-functional workflows to accelerate the transition from preclinical development to commercial-scale manufacturing. By optimizing operational efficiency, Nicholas Crowe supports the rapid deployment of new treatments into the global market. The Chief Operating Officer collaborates with research teams to ensure that manufacturing capabilities align with the evolving needs of the clinical pipeline. Ultimately, Crowe drives the operational excellence necessary to maintain the competitive edge of the company in the complex biotechnology sector.
Matthew Argano - Chief Human Resources Officer
Matthew Argano, the Chief Human Resources Officer at Revance Therapeutics, directs the talent acquisition and organizational development strategies essential for a high-growth biotechnology firm. Overseeing recruitment, employee retention, and corporate culture, the Chief Human Resources Officer ensures the company attracts top-tier scientific and commercial talent to support the development of DaxibotulinumtoxinA. This leadership role involves designing performance management systems that align individual contributions with the broader mission of delivering innovative patient solutions. By fostering an inclusive and high-performance environment, Matthew Argano drives employee engagement across all regional offices. The Chief Human Resources Officer works closely with the executive team to build a workforce capable of navigating the complexities of clinical trials and commercialization. Ultimately, Argano secures the human capital required to sustain the long-term success of the organization.
Steven Kreider - Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics
Steven Kreider, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics at Revance Therapeutics, drives the commercial strategy and market penetration for the company's portfolio of aesthetic and therapeutic products. Overseeing sales force deployment and market access initiatives, the Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics ensures that the value proposition of DaxibotulinumtoxinA reaches key healthcare providers and patient populations. This leadership role involves analyzing regional market dynamics to maximize revenue growth and brand adoption. By executing targeted commercial campaigns, Steven Kreider expands the footprint of the company within the competitive pharmaceutical landscape. The Executive Vice President & Chief Revenue Officer, Aesthetics & Therapeutics collaborates with marketing and clinical teams to refine product positioning and drive demand. Ultimately, Kreider secures the commercial success of the firm through strategic market engagement.
Kira Schwartz - Chief Legal Officer
Kira Schwartz, the Chief Legal Officer at Revance Therapeutics, directs the legal and compliance framework governing the development and commercialization of biotechnology products. Overseeing intellectual property protection, regulatory filings, and corporate governance, the Chief Legal Officer ensures that all clinical trials and business activities adhere to strict industry standards. This leadership role involves managing complex legal risks associated with the patenting of novel botulinum toxin formulations and the expansion of therapeutic indications. By providing strategic counsel to the executive team, Kira Schwartz mitigates potential liabilities and protects the proprietary assets of the company. The Chief Legal Officer coordinates with regulatory bodies to facilitate smooth product approvals and market entry. Ultimately, Schwartz secures the legal integrity of the organization, allowing the firm to innovate with confidence in a highly regulated environment.
Explore Leadership Teams in Manufacturing
Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes medicines for serious diseases with significant unmet medical needs. Its portfolio includes therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. The company also advances research programs in kidney disease, type 1 diabetes, myotonic dystrophy, and other genetic disorders, serving patients through healthcare providers, specialty pharmacies, hospitals, and distributors worldwide.
Company Leadership GL
AL
OG
Bristol-Myers Squibb operates as a global biopharmaceutical organization dedicated to discovering, developing, and manufacturing prescription medications that address serious patient needs across multiple therapeutic domains. The company's scientific expertise spans oncology, cardiovascular disease, immunoscience, and virology, with particular depth in treating complex conditions including HIV and cancer. Through sustained investment in research and development, the organization has built a comprehensive medication portfolio that combines innovative cancer immunotherapies, anticoagulant therapies, and treatments for chronic viral infections. The company's operational footprint extends across major markets worldwide, enabling efficient distribution and patient access to its therapeutic solutions. Bristol-Myers Squibb pursues a collaborative approach to medical innovation, actively engaging in research partnerships and strategic alliances that accelerate the development of new treatment options. This commitment to external collaboration complements the organization's internal capabilities, creating a dynamic environment where scientific breakthroughs can translate into meaningful therapeutic advances. Bristol-Myers Squibb's medication portfolio reflects decades of pharmaceutical expertise and a strategic focus on disease areas where unmet medical needs remain significant.
Company Leadership IC
HA
NM
BS
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.
Company Leadership TI
RN
FA
TriRx Pharmaceuticals is a contract development and manufacturing organization specializing in both non-sterile and sterile products, including animal health injectables and packaging solutions. The company offers a wide range of capabilities such as development and analytics, sterile and non-sterile manufacturing, and packaging services. With facilities located in Huntsville, Alabama, and Segré, France, TriRx aims to support customers' commercialization efforts across global markets. Their target clients include pharmaceutical companies looking for advanced solutions to bring their products to market.
Company Leadership TT
JS
KL
RM
Frequently Asked Questions Regarding Revance Therapeutics Top Executives and Leadership Team
